AUM: $4.7B · Form ADV, 28 Aug 2026
| i | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nasdaq: NRIX | Current | Pharmaceutical Preparations | COM | 7,901,085 | +3,827,298 | +93.9% | 7.23% | $187M | +$89M | 13.71% | $1.5B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: KRYS | Current | Biological Products, (No Diagnostic Substances) | COM | 527,684 | -104,321 | -16.5% | 1.78% | $175M | -$59M | 12.84% | $9.4B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: SRRK | Current | Biological Products, (No Diagnostic Substances) | COM | 3,033,962 | -1,277,130 | -29.6% | 2.49% | $147M | -$91M | 10.73% | $6.1B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: STOK | Current | Pharmaceutical Preparations | COM | 3,869,028 | -76,892 | -1.9% | 5.92% | $101M | -$29M | 7.36% | $1.8B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: IMNM | Current | Pharmaceutical Preparations | COM | 4,363,064 | -548,526 | -11.2% | 3.70% | $94M | -$10M | 6.87% | $2.0B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ABSI | Current | Services-Commercial Physical & Biological Research | COM | 6,671,377 | -68,298 | -1.0% | 3.86% | $72M | -$6M | 5.26% | $1.4B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ETRA | Current | Biological Products, (No Diagnostic Substances) | COM | 5,430,918 | +5,430,918 | New | 8.64% | $61M | +$61M | 4.47% | $561M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ANNX | Current | Pharmaceutical Preparations | COM | 14,278,075 | +2,408,198 | +20.3% | $60M | -$7M | 4.42% | $651M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| Neurogene Inc. | Nasdaq: NGNE | Current | Pharmaceutical Preparations | COM | 1,562,199 | +150,000 | +10.6% | 7.55% | $43M | -$1.0M | 3.18% | $475M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| REGENXBIO Inc. | Nasdaq: RGNX | Current | Biological Products, (No Diagnostic Substances) | COM | 5,048,502 | +679,698 | +15.6% | 7.64% | $38M | -$14M | 2.78% | $475M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Shattuck Labs, Inc. | Nasdaq: STTK | Current | Pharmaceutical Preparations | COM | 5,086,990 | -1,805,043 | -26.2% | 4.99% | $35M | -$13M | 2.54% | $463M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: FATE | Current | Biological Products, (No Diagnostic Substances) | COM | 12,872,946 | 0 | 0.0% | 10.59% | $31M | -$4M | 2.23% | $123M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Silence Therapeutics plc | Nasdaq: SLN | Current | Pharmaceutical Preparations | ADS | 2,460,894 | +296,117 | +13.7% | 1.32% | $27M | +$3M | 1.97% | $1.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: BEAM | Current | Biological Products, (No Diagnostic Substances) | COM | 1,061,782 | -102,477 | -8.8% | 1.03% | $26M | -$14M | 1.90% | $2.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Attovia Therapeutics, Inc. | Nasdaq: ATTO | Current | Biological Products, (No Diagnostic Substances) | COM | 1,163,587 | +1,163,587 | New | 2.55% | $20M | +$20M | 1.46% | $712M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| AgomAb Therapeutics NV | Nasdaq: AGMB | Current | Biological Products, (No Diagnostic Substances) | SPONSORED ADS | 1,740,230 | -993,696 | -36.3% | $19M | -$16M | 1.41% | $277M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: NUVB | Current | Pharmaceutical Preparations | COM CL A | 3,031,009 | 0 | 0.0% | 0.86% | $17M | -$0.2M | 1.24% | $1.3B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ADRX | Current | Pharmaceutical Preparations | COM | 769,345 | +769,345 | New | 0.69% | $15M | +$15M | 1.12% | $1.6B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: IDYA | Current | Pharmaceutical Preparations | COM | 381,319 | -258,883 | -40.4% | 0.39% | $15M | -$9M | 1.07% | $2.5B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| ADC Therapeutics SA | NYSE: ADCT | Current | Pharmaceutical Preparations | SHS | 11,584,552 | +57,842 | +0.5% | 9.07% | $14M | +$2M | 1.03% | $183M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: SLDB | Current | Biological Products, (No Diagnostic Substances) | COM NEW | 1,944,342 | -4,353 | -0.2% | 1.74% | $14M | -$5M | 1.03% | $719M | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ZYME | Current | Pharmaceutical Preparations | COM | 491,654 | 0 | 0.0% | 0.71% | $13M | +$0.2M | 0.95% | $1.9B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Obsidian Therapeutics, Inc. | Nasdaq: OBX | Current | Pharmaceutical Preparations | COM | 833,157 | +833,157 | New | 1.35% | $11M | +$11M | 0.84% | $751M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: BMRN | Current | Pharmaceutical Preparations | COM | 189,538 | -75,631 | -28.5% | 0.10% | $11M | -$4M | 0.83% | $11.9B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CLYM | Current | Pharmaceutical Preparations | COM | 974,489 | -251,841 | -20.5% | 1.66% | $11M | -$5M | 0.82% | $545M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CLDX | Current | In Vitro & In Vivo Diagnostic Substances | COM NEW | 321,770 | -112,151 | -25.8% | 0.41% | $10M | -$6M | 0.76% | $2.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ALXO | Current | Pharmaceutical Preparations | COM | 7,185,263 | -207,241 | -2.8% | 5.56% | $10M | -$5M | 0.73% | $132M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Aura Biosciences, Inc. | Nasdaq: AURA | Current | Biological Products, (No Diagnostic Substances) | COM | 1,552,479 | -114,188 | -6.9% | 1.49% | $10M | -$2M | 0.71% | $726M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: COGT | Current | Pharmaceutical Preparations | COM | 296,606 | -206,715 | -41.1% | 0.17% | $9M | -$10M | 0.70% | $4.8B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CBLL | Current | Electromedical & Electrotherapeutic Apparatus | COM | 386,786 | 0 | 0.0% | 1.00% | $9M | +$2M | 0.69% | $1.0B | Q3 2026 | 16 Nov 2026 | Q4 2024 | Q3 2026 | 13F, Q3 2026 | |
| Odyssey Therapeutics, Inc. | Nasdaq: ODTX | Current | Biological Products, (No Diagnostic Substances) | COMMON STOCK | 374,510 | -50,490 | -11.9% | 0.78% | $8M | +$0.4M | 0.61% | $882M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: XENE | Current | Pharmaceutical Preparations | COM | 191,036 | -38,338 | -16.7% | 0.19% | $7M | -$7M | 0.52% | $3.7B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: LIVN | Current | Electromedical & Electrotherapeutic Apparatus | SHS | 84,132 | -9,022 | -9.7% | 0.15% | $6M | -$1M | 0.47% | $5.1B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ATRA | Current | Biological Products, (No Diagnostic Substances) | COM NEW | 636,852 | +195,151 | +44.2% | 6.25% | $5M | +$0.3M | 0.40% | $65M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: INSM | Current | Pharmaceutical Preparations | COM PAR $.01 | 42,902 | -8,332 | -16.3% | 0.02% | $5M | -$0.6M | 0.36% | $31.7B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| EUPRAXIA PHARMACEUTICALS INC. | Nasdaq: EPRX | Current | Pharmaceutical Preparations | COM | 519,881 | -91,519 | -15.0% | $5M | +$0.7M | 0.35% | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: DBVT | Current | Biological Products, (No Diagnostic Substances) | SPONSORED ADS | 373,417 | -37,023 | -9.0% | 0.12% | $4M | -$2M | 0.32% | $592M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ORIC | Current | Pharmaceutical Preparations | COM | 292,817 | -69,193 | -19.1% | 0.28% | $4M | +$0.0M | 0.29% | $800M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| TCGX Acquisition Corp. | Nasdaq: TCGX | Current | Blank Checks | ORD CL A | 299,860 | +299,860 | New | $4M | +$4M | 0.27% | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: PRME | Current | Biological Products, (No Diagnostic Substances) | COM | 1,146,860 | -242,772 | -17.5% | 0.63% | $4M | -$2M | 0.26% | $856M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: IVVD | Current | Biological Products, (No Diagnostic Substances) | COM | 2,285,320 | -312,439 | -12.0% | 0.77% | $2M | -$0.3M | 0.15% | $132M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| OCULAR THERAPEUTIX, INC | Nasdaq: OCUL | Current | Pharmaceutical Preparations | COM | 243,954 | +243,954 | New | 0.11% | $2M | +$2M | 0.14% | $1.3B | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: ARDX | Current | Pharmaceutical Preparations | COM | 523,870 | -117,880 | -18.4% | 0.21% | $2M | -$1M | 0.13% | $769M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: PLRX | Current | Pharmaceutical Preparations | COM | 772,126 | 0 | 0.0% | 1.25% | $0.8M | -$0.0M | 0.06% | $38M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Augmedix Inc | Exited | COM | 0 | -16,380,327 | -100.0% | -$38M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| Catalent Inc | Exited | COM | 0 | -595,570 | -100.0% | -$36M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| Akero Therapeutics Inc | Exited | COM | 0 | -747,818 | -100.0% | -$36M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| Nasdaq: KYMR | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -803,289 | -100.0% | -$35M | $10.2B | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| RAPT Therapeutics | Exited | COM NEW | 0 | -885,927 | -100.0% | -$30M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| 89bio Inc | Exited | COM | 0 | -1,473,136 | -100.0% | -$22M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| NYSE: HNGE | Exited | Services-Computer Processing & Data Preparation | CL A | 0 | -300,000 | -100.0% | -$16M | $8.8B | Q3 2025 | 14 Nov 2025 | Q2 2025 | Q2 2025 | 13F, Q2 2025 | ||||
| NYSE: SYK | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -30,676 | -100.0% | -$11M | $118B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Nasdaq: REPL | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -1,099,756 | -100.0% | -$11M | $1.8B | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||
| NYSE: BHVN | Exited | Pharmaceutical Preparations | COM | 0 | -729,515 | -100.0% | -$10M | $2.1B | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| NYSE: BSX | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -85,301 | -100.0% | -$9M | $62.3B | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| Nasdaq: ISRG | Exited | Orthopedic, Prosthetic & Surgical Appliances & Supplies | COM NEW | 0 | -16,943 | -100.0% | -$9M | $138B | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||
| Keros Therapeutics, Inc. | Nasdaq: KROS | Exited | Pharmaceutical Preparations | COM | 0 | -552,506 | -100.0% | -$9M | $224M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | |||
| Nasdaq: IMVT | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -490,394 | -100.0% | -$8M | $6.7B | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Verve Therapeutics Inc | Exited | COM | 0 | -740,261 | -100.0% | -$8M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||||
| Establishment Labs Hldgs Inc | Exited | COM | 0 | -88,964 | -100.0% | -$8M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q2 2026 | 13F, Q2 2026 | ||||||
| Nasdaq: PODD | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -27,109 | -100.0% | -$7M | $9.5B | Q2 2025 | 14 Aug 2025 | Q4 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Nasdaq: BNTX | Exited | Biological Products, (No Diagnostic Substances) | SPONSORED ADS | 0 | -73,071 | -100.0% | -$7M | $20.2B | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Exited | COM | 0 | -777,178 | -100.0% | -$6M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | |||||||
| Nasdaq: IRTC | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -56,844 | -100.0% | -$6M | $3.2B | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||
| NYSE: PEN | Exited | Surgical & Medical Instruments & Apparatus | COM | 0 | -18,818 | -100.0% | -$5M | $12.6B | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| Masimo Corp | Exited | COM | 0 | -26,062 | -100.0% | -$4M | Q2 2025 | 14 Aug 2025 | Q1 2025 | Q1 2025 | 13F, Q1 2025 | ||||||
| Repare Therapeutics Inc | Exited | COM | 0 | -1,586,174 | -100.0% | -$4M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| Stereotaxis, Inc. | NYSE: STXS | Exited | Electromedical & Electrotherapeutic Apparatus | COM NEW | 0 | -1,799,465 | -100.0% | -$4M | $102M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | |||
| Nasdaq: ORKA | Exited | Pharmaceutical Preparations | COM | 0 | -386,963 | -100.0% | -$4M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | |||||
| Xeris Biopharma Holdings, Inc. | Nasdaq: XERS | Exited | Pharmaceutical Preparations | COM | 0 | -451,099 | -100.0% | -$4M | $3.0B | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | |||
| Ventyx Biosciences Inc | Exited | COM | 0 | -1,073,386 | -100.0% | -$3M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| Igm Biosciences Inc | Exited | COM | 0 | -2,952,131 | -100.0% | -$3M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||||
| Nasdaq: CYTK | Exited | Pharmaceutical Preparations | COM NEW | 0 | -82,098 | -100.0% | -$3M | $7.2B | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| Lava Therapeutics NV | Exited | SHS | 0 | -2,074,372 | -100.0% | -$3M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||||
| Gritstone Bio | Exited | COM | 0 | -4,920,178 | -100.0% | -$3M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| AC Immune SA | Nasdaq: ACIU | Exited | Pharmaceutical Preparations | SHS | 0 | -1,034,299 | -100.0% | -$3M | $212M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | |||
| Cabaletta Bio, Inc. | Nasdaq: CABA | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -442,826 | -100.0% | -$2M | $218M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | |||
| Achilles Therapeutics PLC | Exited | SPONSORED ADS | 0 | -1,608,089 | -100.0% | -$2M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Astria Therapeutics Inc | Exited | COM | 0 | -269,078 | -100.0% | -$1M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Allovir Inc | Exited | COM | 0 | -1,907,969 | -100.0% | -$0.8M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Kalaris Therapeutics, Inc. | Nasdaq: KLRS | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -82,955 | -100.0% | -$0.7M | Q1 2026 | 15 May 2026 | Q1 2025 | Q4 2025 | 13F, Q4 2025 | ||||
| Nasdaq: FDMT | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -112,168 | -100.0% | -$0.4M | $604M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | ||||
| OTC: ADAPY | Exited | Biological Products, (No Diagnostic Substances) | SPONDS ADR | 0 | -715,607 | -100.0% | -$0.4M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | |||||
| Nasdaq: BOLD | Exited | Pharmaceutical Preparations | COM | 0 | -245,458 | -100.0% | -$0.3M | $56M | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Hookipa Pharma Inc | Exited | COM NEW | 0 | -106,376 | -100.0% | -$0.2M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Allakos Inc | Exited | COM | 0 | -856,615 | -100.0% | -$0.2M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 |